Snap Chart

Navigating Uncertainty: Healthcare Private Equity 2026 Midyear Update

Deal activity moderated from year-end levels but remains robust amid continued volatility.

By Nirad Jain, Kara Murphy, Dmitry Podpolny, Dieter Meyer, Vikram Kapur, Arjun Upmanyu, and Evan Dadosky

Published on Ağustos 27, 2026

Two bar charts showing healthcare private equity deal value and deal count from 2016 through the first half of 2026. Both measures peaked in 2021 (at $151 billion and 515 deals) before moderating; in the first half of 2026, deal value fell to $51 billion from $61 billion a year earlier, while deal count rose to 184 from 173.

Stacked bar chart showing quarterly healthcare private equity deal count by region from Q1 2025 through Q2 2026, with totals peaking at 141 in Q3 2025, dipping to 85 in Q1 2026, and recovering to 99 in Q2 2026—roughly flat versus 100 in Q2 2025—as North America's share increased.

Line chart showing the number of healthcare private equity funds participating in deals by region from 2019 to 2025: North America and Asia-Pacific traded the lead a couple of times, with Asia-Pacific spiking above North America in both 2021 and 2023, before North America pulled ahead for good over the past two years to end at 366, well above Europe, which stayed lowest throughout. A companion bar chart shows total active participating funds worldwide grew from 331 in the first half of 2025 to 415 in the first half of 2026.

Matrix chart plotting AI disruption potential across four healthcare subsectors—provider, payer, pharma and medtech, and healthcare IT—on a spectrum from augmentation to transformation to revolution, with revenue-cycle management and utilization-management functions clustering toward higher disruption and functions like provider clinics and manufacturing skewing toward augmentation.

2026 dealmaking
Deal count by region
Fund activity
AI disruption potential

Global healthcare buyout deal activity moderated in the first half of 2026, with disclosed deal value falling below that of the first half of 2025, even as volume edged higher. The momentum characterizing the second half of 2025 waned as a wave of uncertainty—the AI-driven “SaaSpocalypse,” the Iran war, and redemption stress in the private credit market—weighed on activity.

Regionally, North America saw buyout value rise appreciably in the first half of 2026 compared to 2025, on volume that was broadly equivalent to a year ago. In Europe, volume remained mostly stable year over year, though disclosed value fell meaningfully. Asia-Pacific activity was roughly in line with the year-ago period.

Provider-related transaction value increased significantly in the first half of 2026, driven by multiple transactions spanning a range of subsectors, including both care delivery and healthcare IT/tech services, rather than reflecting one investment theme. The “SaaSpocalypse” muted healthcare IT deal activity, with volume in line with the first half of 2025 and value driven mainly by the Ensemble Health Partners transaction. Investors were cautious about bringing assets to the market given current valuation dynamics and showed appetite for areas with clear transformation theses, such as tech-enabled services.

Looking to the second half of 2026, ample dry powder and ongoing pressure to return capital to investors support continued deal activity. Creative deal structures, including take-privates, featured prominently in the first half of the year and may persist. As in the broader private equity landscape, revenue expansion and multiple arbitrage are no longer sufficient to propel returns. In an AI era where “12 is the new 5,” value creation and AI investment posture have become increasingly important considerations for winning investments.